BC Week In Review | Feb 16, 2018
Clinical News

Alopexx reports Phase I data for bacterial infection prevention candidate

In October, Alopexx Vaccine LLC (Concord, Mass.) reported data from a Phase I trial in 16 healthy volunteers showing that 75-150 μg doses of bacterial infection prevention candidate AV0328 were well tolerated. Alopexx said the...
Items per page:
1 - 1 of 1